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INTRODUCTION
Head and neck squamous cell carcinoma (HNSCC) 
is the sixth most common cancer worldwide and although 
clinical therapies have improved, local recurrence and 
metastasis have stagnated the overall prognosis at 50% 
survival for decades [1, 2]. A subset of these cancers, 
oropharyngeal squamous cell carcinomas (OPSCC), are 
increasing at near epidemic rates [3]. In the majority of 
these cases (60–80%) human papillomavirus (HPV) 
is the causative agent [4]. Despite highly successful 
clinical management of primary OPSCC disease 
(80–90% five year survival), loco-regional spread and 
distant metastasis remain the main cause of mortality 
for HPV+ OPSCC patients [5–6]. These clinical findings 
emphasize the need for establishing and characterizing a 
physiologically relevant animal model of metastatic HPV+ 
OPSCC. Recent studies have increased the mechanistic 
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ABSTRACT
Human papillomavirus induced (HPV+) cancer incidence is rapidly rising, 
comprising 60–80% of oropharyngeal squamous cell carcinomas (OPSCCs); while 
rare, recurrent/metastatic disease accounts for nearly all related deaths. An in vivo 
pre-clinical model for these invasive cancers is necessary for testing new therapies. 
We characterize an immune competent recurrent/metastatic HPV+ murine model 
of OPSSC which consists of four lung metastatic (MLM) cell lines isolated from an 
animal with HPV+ OPSCC that failed cisplatin/radiation treatment. These individual 
metastatic clonal cell lines were tested to verify their origin (parental transgene 
expression and define their physiological properties: proliferation, metastatic 
potential, heterogeneity and sensitivity/resistance to cisplatin and radiation. All MLMs 
retain expression of parental HPV16 E6 and E7 and degrade P53 yet are heterogeneous 
from one another and from the parental cell line as defined by Illumina expression 
microarray. Consistent with this, reverse phase protein array defines differences 
in protein expression/activation between MLMs as well as the parental line. While 
in vitro growth rates of MLMs are slower than the parental line, in vivo growth of 
MLM clones is greatly enhanced. Moreover, in vivo resistance to standard therapies 
is dramatically increased in 3 of the 4 MLMs. Lymphatic and/or lung metastasis 
occurs 100% of the time in one MLM line. This recurrent/metastatic model of HPV+ 
OPSCC retains the characteristics evident in refractory human disease (heterogeneity, 
resistance to therapy, metastasis in lymph nodes/lungs) thus serving as an ideal 
translational system to test novel therapeutics. Moreover, this system may provide 
insights into the molecular mechanisms of metastasis.
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understanding of metastasis however, the lack of clinical 
survival benefit underscores that this knowledge remains 
incomplete. In vivo pathways governing the “invasion-
metastasis cascade” [7] include: invasion, intravasation, 
survival of circulating tumor cells, extravasation, 
microscopic induction and subsequent macroscopic 
outgrowth at a secondary site. These biologically complex 
events are difficult to model in vitro; moreover, epithelial-
mesenchymal plasticity is profoundly influenced by non-
tumor cells including endothelial, fibroblasts, stromal, and 
infiltrating immune cells in the tumor microenvironment 
[8]. Additionally, cytokine and chemokine signals from 
distant organs influence tumor cell exosome secretion, 
thus establishing unique secondary organ niches capable 
of sustaining metastatic tumor growth [9–10]. Thus, in 
addition to yielding mechanistic insights into metastasis, 
disease specific animal models that faithfully replicate 
clinical disease progression as well as resistance to therapy, 
and route/site of metastatic outgrowth are essential for 
defining prophylactic and metastatic treatment regimens. 
In this article, we characterize a new transplantable 
syngeneic mouse model of metastatic HPV+ OPSCC. Four 
unique metastatic cell lines were isolated from an HPV+ 
murine model previously described by our laboratory 
[11]. The parental mouse oropharyngeal epithelial cells 
stably transformed with HPV16 E6 and E7 together with 
hRas and luciferase, (mEERL) and the newly derived 
mEERL lung metastasis cell lines (MLMs) maintain the 
cellular effects of these driver oncogenes. Notably, the 
MLM cell lines possess heterotypic traits in both their 
physiologic and molecular characteristics, replicating 
the heterogeneity widely described of metastatic tumors 
[12–13]. Additionally, these cell lines display differences 
in sensitivity to standard of care treatment modalities 
(cisplatin and radiation) and more aggressive growth 
in vivo than their parental cells, consistent with two 
common characteristics of metastatic cancers [14]. Finally, 
when re-implanted in immune competent mice, the MLM 
cell lines metastasize at an increased rate developing 
metastatic outgrowth within a reasonable time frame 
(30–40 days). Importantly, MLM metastasis mimics the 
sites of spread occurring in human disease (draining 
lymph nodes and lung). Finally, not only do the parental 
mEERL cells share characteristics with human HPV+ 
OPSCCs but so do the MLM cell lines. The combination 
of these characteristics suggests that this unique metastasis 
model holds great translational potential for testing new 
adjuvant therapies for HPV+ OPSCC. 
RESULTS
Isolation of tumor clones 
During routine tumor measurements for a mouse 
study investigating the role of HPV16 E6/E7 in OPSCC, 
one animal with a late growing recurrent tumor developed 
ascites. This mouse had been injected with 1 × 106 
mEERL cells [15] and treated with cisplatin/radiation 
therapy (CRT): three weekly doses of cisplatin (20 mg/kg) 
and x-ray radiation (8 Gy) on days 10, 17, and 24. 
Although tumor volume measurements suggested the 
mouse had cleared its disease, residual tumor outgrowth 
became evident at day 96. Upon reaching sacrifice criteria, 
post mortem dissection revealed numerous lung tumors 
(Figure 1A). The lungs were removed and individual 
tumors isolated. Twelve lung tumors were harvested 
and tentatively named mEERL Lung Metastasis clones 
(MLM). Tumors were dissociated, seeded and expanded 
in vitro; five clones survived of which one, MLM#7, 
senesced. The four remaining clones were epithelial 
in morphology (Supplementary Figure 1) and further 
characterized. 
Identification of lung tumors as mEERL 
metastatic clones
To verify that the MLM clones metastasized from 
the originally implanted parental mEERL tumor, MLM 
cell lines were assayed for mEERL transgene expression. 
The parental mEERL cells stably express HPV16 E6/E7, 
hRas, and luciferase. All MLM clones, except MLM#3, 
harbor significant luciferase expression (p ≤ 0.001) 
(Figure 1B). mEER cells (stably expressing HPV16 E6/E7 
and hRas), parent to mEERL cells, served as control. PCR 
for HPV16 E6, E7 and hRas confirmed their presence in 
all four MLM clones (#1, #3, #5 and #10) (Figure 1C). 
Primary mouse oropharyngeal epithelial (1°MOE) cells 
serve as a negative control. 
The oncogenic functions of HPV16 E6 and E7 in 
the MLM cells were analyzed as follows. PTPBl (mouse 
ortholog of the human PTPN13 phosphatase) interacts 
with E6 resulting in phosphatase degradation [16]. All 
MLM cell lines demonstrate PTPBl degradation similar 
to the parental mEERL line. Moreover, HPV16 E6 
expression correlates with loss of P53 in all the MLM 
clones as in the parental mEERLs. Finally, the effect 
of E7, hyperphosphorylation of Rb, occurs in all MLM 
clones (Figure 1D). As expected, none of these changes 
occur in the negative control, 1°MOE. Interestingly, all 
MLM lines showed some degree of luciferase expression 
silencing (MLM#3 silencing luciferase completely) while 
retaining HPV16 E6 and E7 function. These data suggest 
that luciferase expression is not necessary or required for 
survival of the MLM cell lines. However, the fact that they 
all retain expression of E6 and E7 suggests the absolute 
requirement of these HPV oncogenes for their survival. 
Taken together, the data demonstrate that the MLM clones 
are true metastatic cell lines derived from the parental 
mEERL tumor.
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Molecular profiles of the MLM clones show 
significant tumor heterogeneity
Using Illumina expression microarray analysis 
we asked whether the MLM lines adequately represent 
the heterotypic nature of metastasis [17–18]. Principal 
component analysis showed that the mEERL samples 
were very distinct from MLM lines (Figure 2A). When 
MLM lines were analyzed alone, significantly fewer 
gene expression differences were present. However upon 
subgroup analysis, the MLMs clustered equidistantly from 
each other, demonstrating genetic heterogeneity among the 
metastatic lines (Figure 2B). 
There are 1,612 differentially expressed genes 
(DEGs) among MLMs (p ≤ 0.05, ANOVA with BY FDR), 
and 1,433 DEGs between the MLM and mEERL lines 
(p ≤ 0.05, T-test with BY FDR). Only 27 genes are shared 
between the two sets of DEGs. Clustering analysis of the 
two sets of DEGs and the shared set demonstrates that 
MLMs are distinct from their parental cell line (mEERL), 
and there are also differences between the MLMs 
(Supplementary Figure 2A and 2B respectively).
To discover pathways enriched in the two sets of 
DEGs and the shared set, Ingenuity Pathway Analysis (IPA®, 
QIAGEN Redwood City, www.qiagen.com/ingenuity) was 
performed. We found many signaling pathways enriched in 
the DEGs obtained from comparison between mEERL and 
MLM lines (Supplementary Table 1). Signaling pathways 
were also enriched in DEGs among MLMs (Supplementary 
Table 2). Interestingly, some signaling pathways such as 
IL-8 and Thrombin were enriched in both sets of DEGs. In 
addition to signaling pathways, a variety of other pathways 
Figure 1: Identification of lung tumors as mEERL lung metastasis. A C57 Bl/6 mouse previously injected with mEERL cells 
presented with ascites and was dissected on day 96 after tumor injection. (A) Photograph showing lung with several metastases (arrows). 
(B) Comparison of luciferase expression in mEER cells, not stably expressing luciferase, with parental mEERL line and the MLM clones. 
Luciferase expression measured as relative light units (RLU) per 10 ug of lysate. Each bar represents an N = 3; values, means ± SEM. 
Statistically significant differences based on ANOVA compared to mEER control: †P ≤ 0.001. Experiments were repeated three times with 
similar results. (C) PCR analysis of HPV 16 E6, E7 and hRas expression in parental mEERL cells and primary mouse oropharyngeal epithelial 
cells (1°MOE) compared to the MLM clones. GAPDH was used as a loading control. (D) Western blot analysis of 1° mouse oropharyngeal 
epithelial cells (1°MOE) with parental mEERL cells and the MLM clones. The cellular effects of HPV16 E6 are shown in PTPBl and P53 
expression. Cellular effects of HPV16 E7 are shown by levels of hyperphosphorylated Rb (pRb). β actin used as loading control.
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are enriched in DEGs among MLMs, suggesting molecular 
mechanisms of heterogeneity. Finally, a collection of 
degradation pathways were enriched in the 27 shared genes 
(Supplementary Table 3).
Reverse phase protein array (RPPA) analysis further 
validated the heterotypic nature of the MLM cell lines, 
(Figure 3A) demonstrating differences in their protein 
expression. In many instances MLM protein expression 
differs significantly from the parental line; most strikingly 
for MLM#1. Taken together, these data are consistent with 
the published literature emphasizing the heterogeneity of 
metastasis. 
mEERL and MLM tumors mimic human 
HNSCC tumor staining profiles
Human metastatic OPSCC samples are rarely 
biopsied, making a direct molecular comparison with 
the MLM clones difficult. While tissue microarrays 
containing limited numbers of metastatic samples are 
commercially available (US Biomax, Inc), the HPV 
status of these samples is unknown limiting their utility 
for our system. Thus, we validated the expression of 
epithelial and tumor markers characteristic of human 
HPV+ OPSCC with the mEERL model of primary disease. 
HPV tumor status was confirmed by PCR for HPV16 E6 
(Supplementary Figure 3). Human HPV+ OPSCCs  up-
regulate the cell cycle protein P16 and DNA repair protein 
BRCA2, yet demonstrate low expression of tyrosine kinase 
receptors such as EGFR while maintaining epithelial 
markers including cytokeratin and E-cadherin [19]. 
Immunohistochemical staining shows that similar to 
human HPV+ OPSCCs, mEERL tumors retain expression 
of epithelial markers (cytokeratin and E-cadherin), as 
well as BRCA2 and EGFR while demonstrating increased 
expression of P16 (Figure 3B). These data were correlated 
with the RPPA expression analysis of mEERL and MLM 
clones and further demonstrate that not only are the MLM 
clones heterogenous from their parental mEERL cells but 
also from each other (Figure 3C). 
Cellular physiology of the MLM clones and 
parental mEERL tumor cells
To assess the physiology of the metastatic cell lines, 
cellular in vitro growth rate was analyzed. Cells were 
seeded at sub-confluent levels and cell number followed 
over time. None of the MLM clones demonstrated 
statistically different growth from the parental cells, 
but they show a trend towards slower in vitro growth 
as demonstrated by the doubling time (Figure 4A and 
Supplementary Figure 4A). These data suggest that no 
major changes in growth rate exist between the parental 
mEERL cells and the MLM clones in vitro. 
Since the MLM clones were harvested from a 
mouse with primary tumor recurrence following standard 
cisplatin radiation therapy (CRT), we tested whether 
the MLM clones differ in sensitivity to these treatments 
using an in vitro clonogenic assay. Interestingly, each 
MLM cell line was significantly more resistant than the 
parental mEERL line to the effects of cisplatin, radiation 
and their combination (cisplatin p ≤ 0.01, radiation 
p ≤ 0.001, and cisplatin/radiation p ≤ 0.001) (Figure 4B 
and Supplementary Figure 4B). Additionally, there are 
significant differences between the clones. For cisplatin 
treatment, MLM#1 and #5 are more resistant than MLM#3 
and #10 (p ≤ 0.01); for radiation, MLM#1 is more resistant 
than MLM #3 or MLM#10 (p ≤ 0.01) with none of the 
other clones showing significant differences between each 
other. When cisplatin and radiation treatment modalities 
are combined, MLM#1 and #5 are significantly more 
resistant than MLM#3 and #10 (p ≤ 0.01) . In addition, 
Figure 2: Illumina microarray. (A) Principal component analysis of parental mEERL cells (red) compared to MLM clones (blue). 
(B) Principal component analysis of the MLM clones.
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MLM#1 and MLM#5 differ significantly from each other 
with combined therapy (p = 0.001). These findings suggest 
that treatment resistance accounts, at least in part, for 
metastatic survival of these clones. 
Invasion is often viewed as a requisite event to 
metastasis [20]. Thus, we assessed the migratory and invasive 
potential of the MLM clones using matrigel chambers. In 
the migration assay MLM#3, MLM#5, and MLM#10 show 
a significantly increased migratory capacity compared to 
the parental mEERL cells (Figure 4C and Supplementary 
Figure 4C) (p ≤ 0.01). Additionally, MLM#3 and MLM#5 
are more migratory than MLM#1 and #10 (p ≤ 0.001). While 
all of the MLM clones show slight increases in invasion, 
only MLM#5 was significantly different from the parental 
mEERL cells (p ≤ 0.01) (Figure 4D and Supplementary 
Figure 4D). The lack of invasive differences between clones 
combined with the overall low number of cells showing 
migratory capacity prompted us to investigate the metastatic 
potential of the MLM clones in vivo.
MLM clones are capable of in vivo growth and 
secondary metastasis
To begin characterizing the MLM model system 
in vivo, 5 × 104 mEERL or MLM cells were implanted in 
C57Bl/6 mice. Each mouse developed tumor and tumor 
growth was followed until sacrifice criteria were met. In 
contrast to our in vitro results (Figure 4A) MLM clones #3 
and #5 grew at a vastly increased rate compared to MLM 
#1, #10 or mEERL while MLM#1 and #10 only slightly 
outgrew the parental line (Figure 5A). Consequently, the 
increased tumor growth rate resulted in a statistically 
shorter survival for MLM#3 and MLM#5 (p ≤ 0.007) 
(Figure 5B). 
Given the role of the immune system in recognizing 
and clearing tumors in this HPV+ model of OPSCC [21], 
we wondered if the difference in growth rates was due in 
part to failed immune recognition of these MLM tumors. 
Therefore, the study was repeated in C57Bl6/Rag1 mice 
Figure 3: Protein expression in mEERL, MLMs and human HPV+ OPSCC. (A) Heat map of reverse phase protein array 
analysis of parental mEERL cells and MLM clones performed in triplicate. (B) Immunohistochemical staining of normal tissue (The 
Human Protein Atlas) (38), human HPV+ OPSCC and mEERL tumor for hallmark proteins of OPSCC (Keratin, E-cadherin, P16, BRCA2 
and EGFR). Scale bar, 40 μm. (C) RPPA heatmap of protein expression of four markers (EGFR, BRCA2, E-cadherin and P16) analyzed in 
panel B.  Cytokeratin was not analyzed as it was not included in the RPPA. 
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lacking functional T and B cells. Interestingly, tumor 
growth and survival patterns did not differ from those in 
wildtype C57Bl/6 mice (Figure 5C, 5D). Although we 
cannot rule out a role of the innate immune response, 
these data suggest that the increased in vivo growth rate 
observed in MLM#3 and #5 is not related to evasion of an 
adaptive immune response. 
To assess the metastatic potential of the MLM clones, 
tissue was harvested from these mice. Mice exhibiting gross 
pulmonary metastasis had the primary tumor, draining 
(inguinal) lymph node, and lungs sectioned and stained 
for cytokeratin to visualize epithelial cells. While many 
animals showed no gross evidence of metastasis (notably 
no mice in MLM#5), the limited experimental duration 
(due to rapid primary tumor growth) potentially obscured 
identification of metastatic outgrowth. Of those mice that 
did have macroscopic lung metastasis, positive nodules of 
cytokeratin staining in the inguinal lymph nodes (Figure 
5E) were also present suggesting the MLM lines spread 
via a lymphatic route similar to the human disease [22]. 
Figure 4: In vitro cellular physiology in the MLM clones. (A) In vitro growth rate of the parental mEERL cells compared to the MLM clones.  Growth 
is shown as doubling time (calculated as DT = Tln(2)/ln(xE/xb) where DT is doubling time; T is the time period; and xE or xB is the number of cells at the 
ending or beginning of the time period), each bar represents the mean ± SEM, N = 12 from three independent experiments.  Differences in growth between 
the clones did not show statistically significant differences based on ANOVA (ns., P = 0.192).  (B)  Clonogenic survival of parental mEERL cells compared 
to the MLM clones.  Cells were treated with 2 µM  cisplatin, 4 Gy x-ray radiation or the combination of the two modalities.  Experiments were repeated three 
times with similar results.  Each bar represents an N = 8 from two independent experiments; values, means ± SEM.  Statistically significant differences at 
day 6 after treatment, based on ANOVA: †P ≤ 0.01. (C) Bar graph showing cell migration and (D) invasion on Matrigel chambers.   Bars represent an N = 7, 
experiments were repeated 3 times with similar results; values, means ± SEM.  Statistically significant differences 12 hours after seeding, based on ANOVA: 
†P ≤ 0.01.
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Together, the data demonstrate that MLM cells are not only 
capable of in vivo growth but also metastasis.
In vivo response to standard cisplatin/radiation 
therapy differs between the MLM clones
Because the in vivo growth rate of the clones 
differed from that observed in vitro (Figures 4A and 5A), 
we asked whether the treatment resistance inherent to the 
MLM cell lines in vitro would be retained in vivo. Briefly, 
5 × 104 tumor cells (parental mEERL or the MLM lines) 
were implanted in C57Bl/6 mice. Due to the accelerated 
growth rate of the MLM clones, mice were treated with 
standard CRT therapy early in the disease course, on days 
4, 11, and 18. Although each mouse initially developed a 
palpable tumor, as can be seen in Figure 6A–6E, all mice 
in the parental mEERL (Figure 6A) and MLM #10 (Figure 
6E) groups cleared their primary disease. Of the remaining 
three clones, MLM#3 (Figure 6C) was the most resistant 
to treatment with only a 20% survival rate, while MLM#1 
(Figure 6B) and #5 (Figure 6D) demonstrated 50% and 67% 
survival respectively (Figure 6F). It is notable that although 
the in vitro resistance to cis/xrt is similar between MLM#3 
and MLM#10 (Figure 4B), the survival response in vivo 
differs significantly (p < 0.001, Figure 6F). These data not 
only demonstrate that the MLM clones differ in therapeutic 
resistance from the parental mEERL cells, but also 
exemplify the clonal heterotypic differences in treatment 
response. As in the growth rates, the resistance demonstrated 
in vivo is not completely reflective of those shown in vitro.
MLM clones have an increased rate of metastasis 
when re-implanted in mice
To define the metastatic rate of MLM cells, we 
analyzed their spread to distant organs at equivalent 
end- points. The accelerated growth rate of the MLM 
lines in vivo necessitated that primary tumor sites be 
irradiated in an attempt to prolong survival, thus allowing 
sufficient time for metastatic outgrowth. Briefly, after 
establishment of a palpable primary tumor, each mouse 
was treated with 8 Gy radiation on days 4, 6, and 8 
after tumor implantation. Tumor growth was monitored 
weekly until sacrifice criteria were met in the first mouse 
(day 35); at this time, tissues from all mice were collected. 
Pulmonary metastasis was assessed by cytokeratin 
staining, representative images are shown in Figure 7A. 
Under these conditions, parental mEERL cells failed to 
metastasize while all the MLM clones showed some level 
of pulmonary spread with MLM#3 metastasizing in every 
animal (Figure 7B). Although not statistically different 
from each other, MLM#3 and MLM#5 demonstrate a 
significant increase in number of metastases compared 
to clones #1 and #10 (p ≤ 0.029 ) (Figure 7C). Not only 
did MLM#3 show the highest rate of metastasis but also 
the highest total number of metastatic tumors. These data 
reflect the MLM clones increased resistance to radiation 
(Figure 4B), but also reveal differences in metastatic rate 
between lines with similar radiation resistance (MLM#3 
and MLM#10). Thus, in addition to their heterogeneous 
growth and treatment response, the metastatic clones differ 
in their ability to metastasize to the lung.
DISCUSSION
Clinically relevant animal models must 
recapitulate critical aspects of the human disease. Here, 
we characterize a novel mouse model of recurrent/
metastatic HPV+ OPSCC that faithfully mimics key 
aspects of: 1) heterogeneity, 2) anatomically relevant 
metastasis, and 3) resistance to standard first-line CRT. 
While all MLM cell lines were harvested from the lungs 
of a single mouse injected with clonal parental mEERL 
cells, we show that each metastatic line derived from 
this animal is phenotypically distinct from the parental 
line and also from each other. These differences exist not 
only in gene and protein expression profiles, but also in 
growth rates, resistance to CRT and metastatic potential 
(Figures 2–7). Such heterogeneity is consistent with the 
published literature [23–25]. Interestingly, many of the 
in vitro data were not reflective of in vivo physiology. 
This is likely due to the influence of factors present in the 
tumor microenvironment (stromal and immune cells) that 
are absent in vitro. These differences further emphasize the 
need for in vivo model systems.
On the surface, heterogeneity of solid tumors and 
their metastases presents a bleak outlook for cancer cures. 
However, it is important to note that in this system, all 
MLM cell lines retained the cellular manifestations 
of HPV oncoprotein (E6 and E7) expression strongly 
suggesting that these viral oncogenes drive key pathways 
necessary for tumor cell survival (Figure 1C and 1D). 
These data suggest that while metastatic heterogeneity 
exists, it is likely that common pathways for growth and 
survival are utilized. Once identified, these pathways 
could be therapeutically targeted to control or eliminate 
metastatic growth despite heterogeneity.
Local spread to the draining lymph nodes and 
distant pulmonary metastasis (Figure 5E and Figure 7A) in 
the MLM model system mirror the clinical progression for 
human OPSCC [26–27]. While the percent lung metastasis 
varied among the MLM lines, the finding that they all 
honed to the lung suggests a shared ability to target this 
organ. Further genotype and expression analyses will 
help define the pathways targeting the lung and sustaining 
tumor growth at this site. 
Finally, this recurrent-metastatic mouse model 
demonstrates resistance to standard CRT which is common 
in OPSCC patients that suffer disease recurrence and 
progression [28–29]. Unfortunately, recurrence poses a major 
hurdle for these patients as currently the cancer therapeutic 
arsenal offers little to successfully combat this complication. 
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Figure 5: In vivo growth of MLM clones. Parental mEERL cells and MLM clones were injected into the hind limb of mice (50,000 
cells/mouse N = 5 mice/group) to assess MLM growth in vivo.  (A) Tumor growth and (B) mouse survival in wild type C57Bl6 mice. 
 (C) Tumor growth and (D) mouse survival in immune incompetent Rag1 mice.  Values (A, C) mean, ± SEM.  Kaplan Meier survival plot 
differences (B, D) were calculated by pairwise multiple comparison procedures (Holm-Sidak method): †P ≤ 0.01.  (E) Immunohistochemical 
analysis of tissues harvested from the C57Bl/6  mice, (experiment in panel A).  Pan-cytokeratin staining (brown) indicates epithelial cells in 
each section. 4×, inset, and 40× magnification.  Scale bars represent 100 µm and 1µm respectively.
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Figure 6: In vivo response to standard cisplatin/radiation therapy. Parental mEERL cells and MLM clones were injected into 
the hind limb of C57Bl6 mice (50,000 cells/mouse N = 12 mice/group).  After establishment of palpable tumors, mice were treated with 
IP cisplatin (20 mg/m2) and x-ray radiation (8 Gy) on days 4, 11, and 18.  Individual mouse tumor growth curves for each cell line, panel 
(A) mEERL, (B) MLM#1, (C) MLM#3, (D) MLM#5, and (E) MLM#10.  (F) Kaplan Meier tumor free survival graph.  All non-surviving 
mice were sacrificed due to tumor burden at the primary (hind limb) tumor sight.  Deaths not associated with tumor (death during CRT) 
were censored from the data and are indicated by dots on the corresponding curve.  Statistically significant differences were calculated by 
pairwise multiple comparison procedures (Holm-Sidak method): †P ≤ 0.01.
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This metastatic mouse model offers the ability to test the 
efficacy of drugs emerging from the therapeutic pipeline in 
blocking metastasis and recurrence due to resistance. It is 
important to note that this model is immune competent. This 
is of particular importance to HPV+OPSCCs as the immune 
system plays a significant role in tumor clearance [30]. Thus, 
this model provides a system in which to test new drugs and 
study their interplay with the immune system in controlling 
or eliminating metastatic tumor growth. 
The parental mEERL cell line exemplifies many of 
the original “hallmarks of cancer” described by Hanahan 
and Wienberg over a decade ago [31]. For example, the 
mEERL model system possesses replicative immortality 
[21], sustained proliferative signaling [32–33], resistance 
to cell death (unpublished data), and evasion of growth 
suppressors [34]. Moreover, two emerging hallmarks 
of tumor cells [8] are also exemplified in this model 
system: 1) dysregulation of cellular energetics [35] and 
2) immune evasion [36]. In this report, we describe the 
mEERL model’s ability to replicate the remaining cancer 
hallmarks: invasion and metastasis. Together, the mEERL 
and MLM models provide a system with which to study 
the mechanisms driving tumor growth and metastasis as 
well as providing paradigms for testing new therapies 
aimed at blocking tumor progression and recurrence. The 
metastatic OPSCC model in particular holds great promise 
for clinical advancement in this field as currently patients 
with recurring tumors have limited options. This model 
not only provides an immune competent in vivo system 
for drug testing but also offers a system in which to 
molecularly define metastatic pathways and identify novel 
targets for therapeutic intervention.
Figure 7: Metastatic potential of MLM clones. Parental mEERL cells and MLM clones were injected into the hind limb of C57Bl6 
mice (50,000 cells/mouse N = 8 mice/group) and allowed to establish tumor for 4 days.  The tumor was treated with 8 Gy x-ray radiation 
on days 7, 9, and 11 to slow growth of the primary tumor and increase time for metastasis to develop.  At day 35 all mice were sacrificed. 
(A) Representative IHC image of keratin positive lung metastasis from each clone 4× magnification. Scale bars represent 100 µm. 
(B) Percent of mice from each clone demonstrating lung metastasis. (C) Number of keratin positive metastases per section (7–8 mice per 
group 3 independent sections/mouse); values, mean, ± SEM. Statistically significant differences at day 35 after tumor implantation, based 
on ANOVA: †P ≤ 0.01.
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MATERIALS AND METHODS
Cell lines, culture conditions and authentication
Primary mouse oropharyngeal epithelial cells 
(MOE) from male C57Bl/6 mice were isolated and 
cultured in KSFM medium (Gibco Life Technologies). 
Stable MOE lines expressing HPV16 E6/E7, hRas, and 
luciferase (mEERL) were previously generated and 
maintained in E-media [37] [16] [15]. mEERL lung 
metastasis cells (MLM) were isolated from the lungs 
of a treatment failed mouse. Individual lung metastasis 
were dissected, homogenized and dissociated with 
2 U/mL dispase (Roche) in RPMI1640 with penicillin/
streptomycin and Fungizone (Gibco Life Technologies). 
The resulting cells were washed in PBS resuspended in 
E-media with Fungizone and seeded on 35 mm tissue 
culture dishes. Each metastatic clone was subsequently 
expanded to larger vessels, used for analysis and 
cryopreserved. In this paper, we authenticate the MLM 
cell lines as being derived from the parental mEERL 
tumor (Figure 1). As a further indication that the MLM 
cell lines are murine in origin, we are able to implant 
them into immune competent syngeneic mice and observe 
tumor growth (Figure 5).
Western blot
Cells were grown to 80% confluence and harvested 
in lysis buffer (50 mM Tris HCl pH 7.5, 150 mM NaCl, 
5 mM EDTA, 2 mN Na3VO4, 100 mM NaF, 10 mM 
NaPPi, 10% glycerol, 1% Triton X-100, 17.4 µg/mL 
paramethylsulfonylfluoride, 1X HALT with EDTA), 1% 
Tx-100 and HALT with EDTA (Peirce). Lysates were spun 
at 10,000 RPM for 15 minutes at 4°C. Tx100 soluble cell 
lysates (40 µg /lane) were separated by SDS PAGE and 
analyzed by western blot with the following antibodies: 
PTPBl (scH300 Santa Cruz Biotechnology), P53 (1C12 
Cell Signaling), pRb (sc7905 Santa Cruz Biotechnology), 
and βactin (AC-74 Sigma). Standard HRP secondary 
antibodies (1:10,000) and ECL reagent (Thermo) were 
used for visualization with a CCD camera imaging system 
(UVP).
Luciferase expression
Luciferase expression assays were conducted on 
the soluble fraction of cell lysates harvested as per the 
manufacturer’s instructions (E1500 Promega). Luciferase 
was measured by incubating 10 µg protein lysate with 
50 µl substrate and read on a Promega GLOMAX 96 
microplate luminometer.
PCR and Illumina microarray analysis
RNA was harvested as follows: Cells were grown to 
approximately 80% confluence, rinsed with 1X phosphate 
buffered saline and lysed in 200 µl TRIZOL Reagent 
(Life Technologies) as per the manufacturer’s directions. 
RNA was purified on RNeasy Mini Column (Qiagen) and 
samples were eluted in RNase free deionized water. For 
RT-PCR, cDNA was generated using the Retroscript Kit 
(Life Technologies). Standard PCR was performed to 
assess expression of HPV16 E6, E7, Ras and GAPDH in 
each sample with the indicated primers: 
HPV16 E6 forward primer 5′CAAACCGTTGTGT 
GATTTGTTAATTA 3′ 
HPV16 E6 reverse primer 5′GCTTTTTGTCCAGA 
TGTCTTTGC 3′; 
HPV16 E7 forward primer 5′ ATGCATGGAGATA 
CACCTACATTGCATG 3′
HPV16 E7 reverse primer 5′ TTATGGTTTCTGA 
GAACAGATGGGGC 3′ 
hRas forward primer 5′ ATGACGGAATATAAGC 
TGGTGGTGG 3′
hRas  reverse primer 5′ CATGGCGCTGTACTC 
CTCCTG 3′
GAPDH forward 5′ GGGAAGGTGAAGGTCGG 
AGT-3′ 
GAPDH reverse 5′ TGGAAGATGGTGATGGG 
ATTTC-3′. 
RNA samples were also subjected to gene expression 
profiling using Illumina MouseRef-8 Expression BeadChips 
(Illumina). Raw expression data were subjected to cubic 
spline normalization in GenomeStudio (version 2011.1). 
Principal component analysis (PCA) were performed with 
Partek Genomics Suite (version 6.6) using a significance 
of p < 0.01 as a threshold for gene inclusion. ANOVA and 
T-test were performed using in-house R scripts, and the 
significant genes were obtained using a False Discover 
Rate (FDR: Benjamini–Hochberg–Yekutieli procedure) of 
p < 0.05. Hierarchical clustering was performed using the 
software GENESIS (version 1.7.6). These data have been 
deposited in GEO (accession # GSE68935).
Reverse phase protein microarray (RPPA)
Briefly, lysates from mEERL and MLM clones 
were harvested from 35 mm dishes grown to 80% 
confluence and shipped to: MD Anderson Core Facility – 
Functional Proteomics – RPPA (http://www.mdanderson.
org/education-and-research/resources-for-professionals/
scientific-resources/core-facilities-and-services/functional-
proteomics-rppa-core/index.html) for analysis. Heatmap 
was generated using protein expression profiles across 
samples. Proteins and samples were clustered using an 
average linkage hierarchical clustering algorithm. 
Cell proliferation assay
Cellular growth rate was determined by seeding 
5000 cells per well in 12 well plates. Time points were 
collected in triplicate by washing in PBS–/– with 2 mM 
EDTA and harvesting with TrypLE (Life Technologies) 
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at 24, 48, 72, and 96 hours. All replicates were counted 
on a Cell Countess system (Invitrogen). Doubling times 
were calculated as DT = Tln(2)/ln(xE/xB) where DT is 
doubling time; T is the time period; and xE or xB is the 
number of cells at the ending or beginning of the time 
period, respectively.
Colony formation
Colony forming assays were conducted by plating 
200 cells per well in 12 well dishes. Six hours after seeding 
1000X cisplatin (Calbiochem) solubilized in DMSO was 
added to a final concentration of 2 µM. Control plates 
and plates receiving radiation alone were treated with 
an equivalent volume of DMSO. Within 10 minutes of 
cisplatin addition, 4 Gy radiation was administered to 
the radiation alone or the cisplatin/radiation conditions. 
Plates were returned to a 37° incubator where colonies 
were allowed to grow for 6 days and subsequently fixed in 
70% ethanol and stained with trypan blue in 10% ethanol. 
Colonies in triplicate wells were counted on a GelCount 
imaging system (OXFORD OPTRONIX) using identical 
settings.
Migration and invasion
Migration and invasion assays were performed 
by seeding 50,000 cells per well in BD BioCoat 
matrigel chambers (BD Biosciences). After 20 hours, 
invading or migrating cells were fixed and stained as 
per the manufacturer’s instructions and counted at 
20X magnification (EVOS cell imaging system, Life 
Technologies).
Animal studies
All animal experiments were approved by the 
Sanford Research IACUC and performed within 
institutional guidelines. Four to six week old, 20–25 gm 
male C57BlJ/6 mice or C57BlJ/6 Rag 1 mice (The Jackson 
Laboratory) were maintained at the Sanford Research 
Laboratory Animal Research Facility in accordance with 
USDA guidelines. Tumors were initiated as follows: 
using a 23-gauge needle mEERL or MLM cells were 
implanted subcutaneously in the right hind flank of mice 
(n = 10/group). For the indicated schedule, mice were 
anesthetized with 87.5 mg/Kg ketamine and 12.5 mg/Kg 
xylazine, and treated with 8 Gy X-ray radiation (RS2000 
irradiator, RadSource Technologies, Inc. Suwanee, GA), 
intraperitoneal cisplatin (CalBiochem) dissolved in 
bacteriostatic 0.9% sodium chloride (Hospira Inc.) at 
20 mg/m2 or the combination of both modalities. Tumor 
growth was measured weekly as previously described 
[15]. Animals were euthanized when tumor size was 
greater than 1.5 cm in any dimension. Conversely, mice 
were considered tumor free when no measurable tumor 
was detected for a period of two months. Survival graphs 
were calculated by standardizing for a tumor volume of 
2500 mm3. Statistical analysis for the survival graphs was 
performed using the log-rank test with α = 0.01.
Human subjects
All human tissues were collected with informed 
consent and approval from Sanford Health IRB 
(#MOD00000135).
Microscopy
Paraffin embedded tissue blocks were prepared, 
sectioned, and stained using standard immunohistochemical 
techniques by the Sanford Molecular Pathology Core. 
Briefly, paraffin embedded tissues were sectioned to 5 μm 
and stained on a BenchMark® XT automated slide stainer 
(Ventana Medical Systems, Inc). Ventana iView DAB 
detection kit and counterstaining with hematoxylin were 
used for visualization. Staining for pan-cytokeratin 
(ab9377, Abcam), E-cadherin (#3195, Cell Signaling), P16 
(MA5-17093, Thermo and #10883-1-AP, ProteinTech), 
BRCA2 (HPA026815, Sigma), and EGFR (ab2430, 
Abcam) were used to visualize tumors of epithelial origin; 
exclusion of primary antibody served as the negative 
control. Lung metastases from three independent sections 
were manually counted on an (Olympus DP71) microscope.
Statistical analysis
For statistical analysis of mircroarray data see PCR 
and Illumina microarray analysis methods. All other 
statistical analyses were performed using Sigma Plot 11 
(Systat Software, Inc.). Survival plots were analyzed using 
Kaplan-Meier survival curves and statistical significance 
was determined by the log-rank test, multiple comparisons 
were made with the Holm-Sidak method. For all other data 
one way ANOVA with the Holm-Sidak pairwise multiple 
comparison procedures were used. An alpha 0.05 was used 
for all tests unless otherwise indicated.
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